Licensing & partnership
Windward Bio Lists on Nasdaq
Windward Bio priced its Nasdaq IPO at $17 per share and began trading as WWB on November 13, 2026. The IPO and a concurrent $50 million Sanofi private placement are expected to raise $225 million before expenses.
Harbour BioMed and Kelun-Biotech licensed WIN378 to Windward Bio in 2025, with up to $970 million in combined upfront and milestone payments plus tiered royalties. WIN378 is being studied globally in the Phase II/III POLARIS asthma trial and Phase II SIRIUS COPD trial.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.